Clinical Trial Update: Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for LX101 in inherited retinal dystrophy, sponsor Innostellar Biotherapeutics Co.,Ltd, currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inherited Retinal Dystrophy

Drugs mentioned

• LX101

Snippet

Sponsor: Innostellar Biotherapeutics Co.,Ltd | Conditions: Inherited Retinal Dystrophy | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING